科创板六周年“再出发”

Core Viewpoint - The article highlights the significant achievements and ongoing reforms of the Sci-Tech Innovation Board (STAR Market) in China over the past six years, emphasizing its role in supporting hard technology enterprises and fostering innovation in the capital market. Group 1: Achievements of the STAR Market - As of July 22, 2025, the STAR Market has 589 listed companies, raising a total of 9,257 billion yuan through IPOs and 1,867 billion yuan through refinancing, totaling over 1.1 trillion yuan [2][5][22]. - The STAR Market has become a vibrant platform for hard technology companies, with over 379 companies recognized as national "specialized and innovative" small giants, and 65 companies designated as "single champion" enterprises in manufacturing [5][22]. - The compound annual growth rates for revenue and net profit attributable to shareholders of STAR Market companies from 2019 to 2024 are 19% and 9%, respectively [5]. Group 2: Institutional Innovations - The STAR Market has implemented a series of institutional innovations, including the "1+6" policy measures aimed at enhancing the capital market's support for technological innovation and new productivity development [3][18]. - The introduction of the "STAR Growth Tier" and related reforms marks a new phase of precise support for technology innovation enterprises [3]. - The STAR Market has established a multi-dimensional regulatory framework that enhances the development environment for technology innovation companies [6]. Group 3: R&D Investment and Innovation - In 2024, the total R&D investment of STAR Market companies reached 168 billion yuan, which is over three times the net profit of the board, with a median R&D intensity of 12.6% [11][29]. - Approximately 30% of STAR Market companies have products or projects that are industry-first, and over 380 companies have products or technologies that meet international advanced standards [32]. - The STAR Market has seen significant contributions to the pharmaceutical sector, with 19 out of 20 companies listed under the fifth set of standards having their self-developed drugs or vaccines approved for sale [6][26]. Group 4: Ecosystem and Talent Attraction - The STAR Market plays a crucial role in facilitating a virtuous cycle among technology, industry, and capital, with over 60% of its founding teams comprising scientists or industry experts [14]. - Nearly 90% of STAR Market companies received venture capital investment before going public, indicating a strong early-stage investment environment [14]. - The STAR Market has developed a comprehensive index system, with 29 indices tracking its performance, and products tracking the STAR Market indices totaling nearly 260 billion yuan [14]. Group 5: Investor Returns and Corporate Governance - In 2024, 509 companies on the STAR Market disclosed plans to enhance quality and efficiency, with over 60% proposing cash dividend plans totaling 38.8 billion yuan [15]. - The STAR Market has seen a record number of share buybacks and increases in shareholding, with 470 instances of buyback plans amounting to nearly 38 billion yuan [15].